Updates to the protocol including: 1) General Information: PI and site details 2) Urine samples and albumin-creatinine ratio: clarified that this test will be taken during the trial 3) Inclusion and exclusion criteria: one inclusion and one exclusion criteria added: • Extra inclusion criteria: Has a need for structured education to optimise diabetes control in the opinion of the investigator. • Extra exclusion criteria: Has a need for pump therapy in the opinion of the investigator. 4) DAFNE pre-course pump session: clarified when pump use on saline would be taking place. Updates to the participant information sheet including: 1) Geographical areas for the trial have been amended according to site removal and additions. 2) Sentence amended to clarify process of continuation of pump therapy in England and Scotland. 3) Northwest 3 Research Ethics Committee-Liverpool East listed as ethics committee for whom approval has been granted. Updates to REPOSE leaflet including: 1) Addition to clarify that urine samples will be taken in addition to blood samples at baseline, 6-, 12- and 24-months Updates to the CTA including: 1) Sites amended 2) Inclusion/exclusion critiera added 3) Contact details, typographical errors and updated details (ethics approval details, ISRCTN number) added

Protocol (NRES & MHRA- substantial amendment) 1) General information - p.4: Change to details of PIs and sponsor contact 2) Protocol amendment details - p.6: Text inserted to detail protocol amendments from version 3 to 4. 3) Trial summary - p.7: List of sites amended to correspond with removal/addition of sites. 4) Demographic measures - p.14: Removal of religion as part of the demographic analyses. 5) Randomisation - p.23: Time at which REPOSE educator finds out which treatment arm participants has been allocated to altered from one month to six weeks. 6) Table 1: Documents for Data collection - p.26-30: Details of severe and moderate hypos recording process amended in table 7) Typographical errors and formatting - References to appendices removed from protocol. Formatting of figures undertaken.

1) Blinded review of HbA1c (measure of the level of blood glucose control) To allow the trial statistician to conduct a blinded review after Course 2, 4 and 5 to examine the proportions of recruited participants who are in each HbA1c category (i.e. ≥7.5% or <7.5%). The trial statistician will look at the proportions in each HbA1c category, and numbers of participants with an HbA1c ≥ 7.5% threatens the ability of the trial to detect a difference in primary outcome (i.e. there are substantially more subjects recruited with an HbA1c <7.5% than anticipated), then an additional inclusion criteria will be added to limit recruitment only to participants with an HbA1c of ≥7.5% in order to ensure the trial can detect a difference in the primary outcome. 2) Withdrawal from the pump criteria Removal of ‘Participant becomes pregnant’ as a reason for withdrawal from the pump. Amended so that the decision as to whether a participant who becomes pregnant during the trial stays on the pump is purely a clinical decision based on the participant’s blood glucose control on the pump i.e. if the participant was managing their diabetes well on the pump, they remain on the pump. 3) To add and remove sites • Addition of Royal Infirmary of Edinburgh (PI: Dr Alan Jaap) • Removal of University of Edinburgh (Dr Julia Lawton) and Monklands Hospital (Dr Thekkepat Sandeep) 4) Notification that Harrogate and District NHS Foundation Trust (PI: Dr Peter Hammond) are delivering part of the trial intervention using a venue that is not owned by Harrogate and District NHS Foundation Trust: Henshaws Society for Blind People, Bogs Lane, Harrogate, North Yorkshire, HG1 4ED.

To increase the number recruited to the study. Drop-outs are occurring prior to DAFNE course attendance and thus these participants do not count towards the ITT. This change does not increase the number of participants who will receive the intervention or comparator treatment.

Updates to the REPOSE Protocol v11: - clarified withdrawal from treatment criteria for participants who develop the need for renal replacement therapy or who are found to be abusing alcohol or drugs - clarified that pregnancies will be recorded as SAEs & that they are exempt from immediate reporting Participant Retention and Return of Data - Where participant do not live locally, appropriate research staff may arrange to visit the participant in their home or at an alternative NHS location to carry out data collection.